[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE425740T1 - Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primarem glaukom - Google Patents

Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primarem glaukom

Info

Publication number
ATE425740T1
ATE425740T1 AT06779382T AT06779382T ATE425740T1 AT E425740 T1 ATE425740 T1 AT E425740T1 AT 06779382 T AT06779382 T AT 06779382T AT 06779382 T AT06779382 T AT 06779382T AT E425740 T1 ATE425740 T1 AT E425740T1
Authority
AT
Austria
Prior art keywords
delivery system
chronotherapeutic
treatment
occular
prostaglandins
Prior art date
Application number
AT06779382T
Other languages
English (en)
Inventor
Barbara Conway
Doina Gherghel
Original Assignee
Univ Aston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0519270A external-priority patent/GB0519270D0/en
Priority claimed from GB0608181A external-priority patent/GB0608181D0/en
Application filed by Univ Aston filed Critical Univ Aston
Application granted granted Critical
Publication of ATE425740T1 publication Critical patent/ATE425740T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06779382T 2005-09-21 2006-09-11 Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primarem glaukom ATE425740T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0519270A GB0519270D0 (en) 2005-09-21 2005-09-21 Chronotherapeutic delivery system for treatment of glaucoma
GB0608181A GB0608181D0 (en) 2006-04-25 2006-04-25 Chronotherapeutic Delivery System For Treatment Of Glaucoma

Publications (1)

Publication Number Publication Date
ATE425740T1 true ATE425740T1 (de) 2009-04-15

Family

ID=37605837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06779382T ATE425740T1 (de) 2005-09-21 2006-09-11 Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primarem glaukom

Country Status (6)

Country Link
US (1) US20090155338A1 (de)
EP (1) EP1928407B1 (de)
AT (1) ATE425740T1 (de)
DE (1) DE602006005826D1 (de)
ES (1) ES2326282T3 (de)
WO (1) WO2007034140A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
US10272035B2 (en) 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US20100158980A1 (en) * 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
WO2010105130A2 (en) * 2009-03-13 2010-09-16 Vista Scientific Llc Opthalmic drug delivery system and applications
EP3785683B1 (de) 2009-05-18 2023-11-01 Dose Medical Corporation Arzneimittelfreisetzendes augenimplantat
WO2012071476A2 (en) 2010-11-24 2012-05-31 David Haffner Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN102596097B (zh) 2009-06-03 2015-05-20 弗赛特实验室有限责任公司 一种眼插入件
US20130142858A1 (en) 2010-05-17 2013-06-06 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP4094734A1 (de) 2011-09-14 2022-11-30 Forsight Vision5, Inc. Augeneinsatzvorrichtung
ES2752028T3 (es) 2012-10-26 2020-04-02 Forsight Vision5 Inc Sistema oftálmico para la liberación sostenida del fármaco en el ojo
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
EP3677229A1 (de) 2014-05-29 2020-07-08 Glaukos Corporation Implantate mit funktionen der kontrollierten arzneimittelfreisetzung
WO2016168141A1 (en) 2015-04-13 2016-10-20 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
WO2016187426A1 (en) 2015-05-19 2016-11-24 Amorphex Therapeutics Llc A device that delivers a sustained low-dose of a myopia-suppressing drug
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
WO2017184881A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
US11672697B2 (en) 2018-06-19 2023-06-13 Twenty Twenty Therapeutics Llc Eye-mountable therapeutic devices, and associated systems and methods
BR112022011067A2 (pt) * 2019-12-10 2022-08-23 Alcon Inc Insertos oculares poliméricos dissolvíveis com um polímero biodegradável

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
PL206594B1 (pl) * 2002-07-15 2010-08-31 Alcon Kompozycja implantu śródocznego i zastosowanie leku oftalmicznego w połączeniu z niskocząsteczkowym związkiem lipofilowym do jej wytwarzania
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods

Also Published As

Publication number Publication date
EP1928407A1 (de) 2008-06-11
EP1928407B1 (de) 2009-03-18
WO2007034140A1 (en) 2007-03-29
DE602006005826D1 (de) 2009-04-30
US20090155338A1 (en) 2009-06-18
ES2326282T3 (es) 2009-10-06

Similar Documents

Publication Publication Date Title
ATE425740T1 (de) Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primarem glaukom
EP4282486A3 (de) Komplementfaktor-b-inhibitor und pharmazeutische zusammensetzung davon, herstellungsverfahren dafür und verwendung davon
DE602007004486D1 (de) Verwendung einer hydrophilen matrix mit einem polyacrylsäurederivat, einem celluloseether und einem sprengmittel zur herstellung eines medikaments zur behandlung von erkrankungen der weiblichen genitalorgane
JP6093701B2 (ja) 眼科用水性組成物
NZ701559A (en) Compositions comprising povidone-iodine
JP2003505422A5 (de)
RU2014133501A (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
MX348525B (es) Proceso para producir poxvirus y composiciones de poxvirus.
DE102005053680A1 (de) Synergistische insektizide Mischungen zur Behandlung von Saatgut
EP2311321A3 (de) Insektizide auf Basis von Neonicotinoiden und ausgewählten Strobilurinen
ATE336247T1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
ATE554747T1 (de) Hochviskose makromolekulare zusammensetzungen zur behandlung von augenerkrankungen
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
ATE482726T1 (de) Neuartiges mittel zur freisetzung von wirkstoffen in dressings mit mindestens einer fettigen substanz
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
DE60026152D1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
MX2009005332A (es) Composicion de control del daño producido por enfermedad de plantas y metodo de prevencion y control del daño producido por enfermedad de plantas.
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
BRPI0408863A (pt) composto, composição farmacêutica, método para tratar doenças, e, uso de um composto.
CL2011001219A1 (es) Composicion que comprende a): 2-[2-(2,5 dimetilfenoximetil)fenil)-2-metoxi-n-metilaceta-mida y b): metconazol o ipconazol, en una relacion en peso de a:b entre 0,0125:1 a 500: 1, y metodo que la aplica a semillas, una planta o el sitio para crecimiento de la planta para asi protegerlas del daño causado por plagas fitopatogenas.
EP4470615A3 (de) Kleine rna als medikament zur vorbeugung und behandlung entzündungsbedingter erkrankungen und kombination davon
WO2008005407A3 (en) Trace amine-associated receptors in the olfactory epithelium

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties